Clinical Application of Fresh Fibroblast Allografts for the Treatment of Diabetic Foot Ulcers: A Pilot Study
Authors:
- Seung-Kyu HanSHSeung-Kyu Han
- Kyu-Jin ChoiKCKyu-Jin Choi
- Woo-Kyung KimWKWoo-Kyung Kim
- 1 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 114 (7) , 1783-1789
Abstract
Diabetic foot ulcers often pose a difficult problem for health care professionals because of the defects associated with fibroblast functioning. Although there has been much interest recently in the use of topical growth factors for the treatment of diabetic foot ulcers, the effects are generally not very dramatic. Cryopreserved fibroblast implants, which are able to adjust to a wound’s environment and provide the desired growth factors and other substances that may be lacking in a chronic wound, represent an exciting development and a major advance. These products may well provide growth factors in the right concentration and in the right sequence, something that has proved difficult to achieve with the topical application of recombinant growth factors. However, cell activities are impaired by cryopreservation. The purpose of this study was to assess the effects of fresh human allogeneic fibroblast grafting for the treatment of diabetic foot ulcers. Eight patients with diabetic foot ulcers ranging from 6 to 17 weeks in duration were treated. The size of the wounds ranged from 2.0 to 6.0 cm2, with three patients exhibiting exposed bones. A history of diabetic foot ulcers was present in five patients. Human dermal fibroblasts from healthy teenagers were cultured in Dulbecco’s modified Eagle medium/Ham’s F-12 supplemented with 10% autologous serum. The cultured cells were applied over the wounds immediately after débridement; fibrin was used as a cell carrier. A dressing was then applied with Tegaderm and kept moist until healing was complete. The progress and time for complete wound closure and patient satisfaction were assessed, with follow-up time ranging from 6 to 18 months. Complete wound healing occurred in all patients. Eleven to 21 days were needed for complete reepithelization of the wound, and no clinical or laboratory abnormalities were noted. Patient satisfaction was also very positive. In this study, the use of fresh human fibroblast allografts was found to be a safe and effective treatment for diabetic foot ulcers.Keywords
This publication has 11 references indexed in Scilit:
- Human Epidermal Growth Factor Enhances Healing of Diabetic Foot UlcersDiabetes Care, 2003
- Wound healing and diabetes mellitusClinics in Plastic Surgery, 2003
- Cytokine manipulation of the woundClinics in Plastic Surgery, 2003
- Cellular Dysfunction in the Diabetic FibroblastThe American Journal of Pathology, 2003
- Collagen synthesis and collagenase activity of cryopreserved heart valvesThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Tissue‐Engineered Product: Allogeneic Cultured Dermal Substitute Composed of Spongy Collagen with FibroblastsArtificial Organs, 2001
- Comparison of the Stress Response to Cryopreservation in Monolayer and Three-Dimensional Human Fibroblast Cultures: Stress Proteins, MAP Kinases, and Growth Factor Gene ExpressionTissue Engineering, 2000
- Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacyWound Repair and Regeneration, 2000
- Growth factors secreted by fibroblasts: role in healing diabetic foot ulcersDiabetes, Obesity and Metabolism, 1999
- Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L‐lactateWound Repair and Regeneration, 1998